Search Results - "Karthaus, M"

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy by Aapro, M., Rugo, H., Rossi, G., Rizzi, G., Borroni, M.E., Bondarenko, I., Sarosiek, T., Oprean, C., Cardona-Huerta, S., Lorusso, V., Karthaus, M., Schwartzberg, L., Grunberg, S.

“…Antiemetic guidelines recommend co-administration of agents that target multiple molecular pathways involved in emesis to maximize prevention and control of…”
Get full text

Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer by Siena, S., Sartore-Bianchi, A., Garcia-Carbonero, R., Karthaus, M., Smith, D., Tabernero, J., Van Cutsem, E., Guan, X., Boedigheimer, M., Ang, A., Twomey, B., Bach, B.A., Jung, A.S., Bardelli, A.

“…Mutations in rat sarcoma (RAS) genes may be a mechanism of secondary resistance in epidermal growth factor receptor inhibitor-treated patients. Tumor-tissue…”
Get full text

Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) by Heinz, W. J., Buchheidt, D., Christopeit, M., von Lilienfeld-Toal, M., Cornely, O. A., Einsele, H., Karthaus, M., Link, H., Mahlberg, R., Neumann, S., Ostermann, H., Penack, O., Ruhnke, M., Sandherr, M., Schiel, X., Vehreschild, J. J., Weissinger, F., Maschmeyer, G.

“…Fever may be the only clinical symptom at the onset of infection in neutropenic cancer patients undergoing myelosuppressive chemotherapy. A prompt and…”
Get full text

Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin: review of the literature by Karthaus, M

“…Major progress for the management of invasive aspergillosis has come from the introduction of new antifungals since the late 1990s. Although mortality of…”
Get full text

Central venous catheter-related infections in hematology and oncology: 2012 updated guidelines on diagnosis, management and prevention by the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology by Hentrich, M., Schalk, E., Schmidt-Hieber, M., Chaberny, I., Mousset, S., Buchheidt, D., Ruhnke, M., Penack, O., Salwender, H., Wolf, H.-H., Christopeit, M., Neumann, S., Maschmeyer, G., Karthaus, M.

“…Cancer patients are at increased risk for central venous catheter-related infections (CRIs). Thus, a comprehensive, practical and evidence-based guideline on…”
Get full text

Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer by Sommerhäuser, G, Kurreck, A, Stintzing, S, Heinemann, V, von Weikersthal, L Fischer, Dechow, T, Kaiser, F, Karthaus, M, Schwaner, I, Fuchs, M, König, A, Roderburg, C, Hoyer, I, Quante, M, Kiani, A, Fruehauf, S, Müller, L, Reinacher-Schick, A, Ettrich, T J, Stahler, A, Modest, D P

“…Initial systemic therapy for patients with metastatic colorectal cancer (mCRC) is usually based on two- or three-drug chemotherapy regimens with…”
Get full text

Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion by Potthoff, K., Hofheinz, R., Hassel, J.C., Volkenandt, M., Lordick, F., Hartmann, J.T., Karthaus, M., Riess, H., Lipp, H.P., Hauschild, A., Trarbach, T., Wollenberg, A.

“…Anti-epidermal growth factor receptor treatment strategies, i.e. monoclonal antibodies such as cetuximab and panitumumab, or epidermal growth factor receptor…”
Get full text

Phase II Dose Escalation Study of Caspofungin for Invasive Aspergillosis by COMELY, O. A, VEHRESCHILD, J. J, HARNISCHMACHER, U, WILKENS, A, FAROWSKI, F, KARTHAUS, M, LEHRNBECHER, T, ULLMANN, A. J, HALLEK, M, GROLL, A. H, VEHRESCHILD, M. J. G. T, WÜRTHWEIN, G, ARENZ, D, SCHWARTZ, S, HEUSSEL, C. P, SILLING, G, MAHNE, M, FRANKLIN, J

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy by Schwartzberg, L., Roeland, E., Andric, Z., Kowalski, D., Radic, J., Voisin, D., Rizzi, G., Navari, R., Gralla, R.J., Karthaus, M.

“…NEPA, an oral fixed combination of the NK1RA netupitant (300mg) and clinically/pharmacologically distinct 5-HT3RA palonosetron (PALO, 0.50mg), is the first…”
Get full text

Guideline based treatment of invasive aspergillosis by Karthaus, M

“…Invasive fungus infections caused by aspergillus spp. occur most frequently in immunocompromised patients. A high infection-associated death rate of up to and…”
Get full text

Diagnosis of invasive fungal infections in hematology and oncology—guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO) by Ruhnke, M., Böhme, A., Buchheidt, D., Cornely, O., Donhuijsen, K., Einsele, H., Enzensberger, R., Hebart, H., Heussel, C.P., Horger, M., Hof, H., Karthaus, M., Krüger, W., Maschmeyer, G., Penack, O., Ritter, J., Schwartz, S.

“…Invasive fungal infections (IFIs) are a primary cause of morbidity and mortality in patients with hematological malignancies. Establishing a definite diagnosis…”
Get full text

Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial by Herrstedt, J., Summers, Y., Jordan, K., von Pawel, J., Jakobsen, A. H., Ewertz, M., Chan, S., Naik, J. D., Karthaus, M., Dubey, S., Davis, R., Fox, G. M.

“…Purpose Chemotherapy-induced nausea and vomiting (CINV) remain significant clinical problems, especially in the delayed phase (24–120 h after chemotherapy)…”
Get full text

Early tumour shrinkage (ETS) and its impact on tumour-related symptoms in patients with previously untreated RAS wild-type metastatic colorectal cancer (mCRC): A retrospective analysis of three panitumumab studies by Taieb, J., Geissler, M., Rivera, F., Karthaus, M., Wilson, R., Loupakis, F., Price, T., Tracy, M., Burdon, P., Peeters, M.

Get full text

A randomized trial on chlorhexidine dressings for the prevention of catheter-related bloodstream infections in neutropenic patients by Biehl, L.M., Huth, A., Panse, J., Krämer, C., Hentrich, M., Engelhardt, M., Schäfer-Eckart, K., Kofla, G., Kiehl, M., Wendtner, C.-M., Karthaus, M., Ullmann, A.J., Hellmich, M., Christ, H., Vehreschild, M.J.G.T.

“…Central venous catheter (CVC)-related bloodstream infections (CRBSI) are a frequent cause of morbidity and mortality in patients with chemotherapy-induced…”
Get full text

Leitliniengerechte Therapie der invasiven Aspergillose by Karthaus, M

“…Invasive fungus infections caused by aspergillus spp. occur most frequently in immunocompromised patients. A high infection-associated death rate of up to and…”
Get full text

Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy—evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO) by Vehreschild, J.J., Böhme, A., Cornely, O.A., Kahl, C., Karthaus, M., Kreuzer, K.-A., Maschmeyer, G., Mousset, S., Ossendorf, V., Penack, O., Vehreschild, M.J.G.T., Bohlius, J.

“…Current evidence on myelopoietic growth factors is difficult to overview for the practicing haematologist/oncologist. International guidelines are sometimes…”
Get full text

Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial by Karthaus, M., Kretzschmar, A., Kröning, H., Biakhov, M., Irwin, D., Marschner, N., Slabber, C., Fountzilas, G., Garin, A., Abecasis, N.G.F., Baronius, W., Steger, G.G., Südhoff, T., Giorgetti, C., Reichardt, P.

“…Background: Cancer patients receiving chemotherapy experience thromboembolic complications associated with the use of long-term indwelling central venous…”
Get full text

P-149Impact of sequence of biologic therapies on overall survival (OS) in patients with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC): an exploratory, retrospective pooled analysis by Sobrero, A, Douillard, J-Y, Rivera, F, get, F, Karthaus, M, Valladares-Ayerbes, M, Demonty, G, Guan, X, Peeters, M

Get full text

PD-031An exploratory study-level meta-analysis assessing the impact of early tumour shrinkage on overall survival in patients with RAS wild-type metastatic colorectal cancer receiving first-line treatment in three randomised panitumumab trials by Rivera, F, Karthaus, M, Valladares-Ayerbes, M, Gallego, J, Koukakis, R, Demonty, G, Douillard, J-Y

Get full text

Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial by Weiss, L., Karthaus, M., Riera-Knorrenschild, J., Kretzschmar, A., Welslau, M., Vehling-Kaiser, U., Pelz, H., Ettrich, T.J., Hess, J., Reisländer, T., Klein, A., Heinemann, V.

“…Trifluridine/tipiracil (FTD/TPI) improved both overall and progression-free survival (OS, PFS) of patients with pre-treated metastatic colorectal cancer (mCRC)…”
Get full text